A recent study validating urine diagnosis for cancer cell receptors in prostate cancer is eclipsing traditional methodology and warrants further steps toward FDA approval says cutting-edge biotechnology leader, NuView Life Sciences. CEO Paul Crowe will present the findings to the Boston Oncology Investor Conference, outlining the steps in the successful study and addressing the technology’s future. …more…
Press Releases
Binding Cell Receptors Key to New Prostate Cancer Diagnostic Test from NuView Life Sciences
Categories
Recent Posts
- Oncology Firm Develops Test for Potential Pediatric Cancers Diagnoses
- Delfi Diagnostics reels in $100M for blood-based cancer test
- Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment
- NuView Life Sciences Develops New Theranostics Approach to Offset High Cost of Cancer Diagnosis, Treatment
- Radiopharmaceuticals Gain Traction for Cancer Theranostics Potential
Recommended For You
Press Releases
Oncology Firm Develops Test for Potential Pediatric Cancers Diagnoses
Karla Jo HelmsFebruary 8, 2021
NewsPress Releases
NuView Life Sciences Develops New Theranostics Approach to Offset High Cost of Cancer Diagnosis, Treatment
Karla Jo HelmsNovember 16, 2020
Press Releases
NuView NV-VPAC1 Uniquely Positioned to Find the Overexpression of Specific Receptors Appearing only on the Surface of Malignant Cells for Early Cancer Diagnosis
Karla Jo HelmsAugust 17, 2020